tripeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. It occurs in nearly all living cells, with highest concentrations in liver, kidney, and red blood cells, and exists in reduced (GSH) and oxidized disulfide (GSSG) forms. The cysteine thiol group enables reversible oxidation and reduction reactions. This property makes glutathione a central participant in cellular redox balance. The balance between these forms is often used as an indicator of oxidative stress.
Glutathione synthesis proceeds in two ATP-dependent steps catalyzed by glutamate-cysteine ligase and glutathione synthetase. The first step joins glutamate and cysteine to form gamma-glutamylcysteine and is generally rate-limiting. The second step adds glycine to complete the tripeptide. Cysteine availability, feedback inhibition by glutathione, and oxidative conditions influence flux through this pathway. The pathway is conserved across many organisms, and degradation by gamma-glutamyl transpeptidase and related peptidases recycles amino acids for new synthesis.
Within cells, glutathione serves as a cofactor for glutathione peroxidases and glutathione S-transferases. These enzymes reduce hydrogen peroxide and organic peroxides or conjugate electrophilic compounds to the thiol group. The resulting conjugates can be exported and processed through mercapturic acid pathways. Glutathione also contributes to protein thiol homeostasis and to recycling of other antioxidants such as ascorbate. Its precise roles vary by tissue, and many regulatory effects observed in laboratory systems remain difficult to quantify in whole organisms.
Measuring glutathione in biological samples requires attention to oxidation, because GSH can convert to GSSG after sample collection. Blood and plasma samples are often treated with acid or alkylating agents to preserve the reduced form. Without stabilization, apparent GSH concentrations can fall while GSSG rises. Differences in sample type, handling delay, and deproteinization method can produce results that are not comparable across studies. Reporting preanalytical details is therefore important for interpreting findings.
Common analytical approaches include enzymatic recycling assays, high-performance liquid chromatography, and mass spectrometry. Enzymatic recycling measures total glutathione after converting GSSG back to GSH, while separation methods can quantify GSH and GSSG separately. Derivatization may be used to improve detection or stability during analysis. LC-MS/MS offers high specificity and can distinguish glutathione from related thiols and adducts. Each method has different sensitivity, throughput, and susceptibility to interference, so method selection depends on the study question and sample matrix.
For solid glutathione reagents, storage at low temperature and protection from moisture and light are typical precautions. Aqueous solutions can oxidize over time, and pH affects stability; alkaline conditions generally promote thiol oxidation. Some protocols prepare fresh solutions, while others use antioxidants or chelators to limit metal-catalyzed oxidation. Purity and counterion content can vary among commercial preparations, affecting concentration calculations. Certificates of analysis and validated assays help verify identity and purity.
| Property | Value | Notes |
|---|---|---|
| Common name | Glutathione | Reduced form is abbreviated GSH |
| Chemical class | Tripeptide | Composed of glutamate, cysteine, and glycine |
| Molar mass | 307.32 g/mol | For reduced glutathione |
| CAS Registry Number | 70-18-8 | For reduced L-glutathione |
| Appearance | White crystalline powder | Typical solid reference material |
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its glutamate-cysteine linkage uses the gamma-carboxyl group of glutamate, a feature that resists standard peptidases. The cysteine residue provides a thiol group, which gives the molecule its reducing character. In cells, glutathione is often the most abundant small-molecule thiol, with concentrations varying widely by tissue and compartment. It exists mainly in a reduced form called GSH, while oxidation produces a disulfide-linked dimer called GSSG.
Biosynthesis proceeds in two ATP-dependent steps. First, glutamate-cysteine ligase joins glutamate and cysteine. Second, glutathione synthetase adds glycine to the intermediate. The pathway is regulated by cysteine availability, enzyme expression, and feedback inhibition by glutathione itself. Liver tissue has a particularly high capacity for synthesis and export. Because the molecule is made inside cells, circulating glutathione reflects a balance of release, uptake, and breakdown rather than simple dietary supply.
Samples for glutathione analysis require careful handling because the compound oxidizes readily and can be consumed by enzymes after collection. Blood is often treated with acid or thiol-blocking agents soon after draw, and plasma should be separated quickly from red blood cells. Tissues are usually snap-frozen or extracted immediately. Aqueous solutions of glutathione are less stable than dry powder and degrade faster at neutral or alkaline pH, in light, or with dissolved oxygen. Repeated freeze-thaw cycles also reduce reliability.
Quality control for glutathione materials checks identity, assay, purity, water content, and disulfide content. Commercial products vary from research-grade powder to dietary supplements, and labels may not distinguish reduced from oxidized forms. In the United States, oral glutathione is commonly sold as a dietary supplement rather than an approved drug, while injectable forms fall under different rules and may require a prescription. Regulatory status differs by country. Analytical certificates, when available, help verify what a material contains, but independent testing remains important for interpretation.
Loop type, in which the primary coolant is circulated through primary heat exchangers outside the reactor tank (but inside the biological shield due to radioactive 24Na in the primary coolant) Pool type, in which the primary heat exchangers and pumps are immersed in the reactor tank There are only two commercially operating breeder reactors as of 2017: the BN-600 reactor, at 560 MWe, and the BN-800 reactor, at 880 MWe. Both are Russian sodium-cooled reactors. The designs use liquid metal as the primary coolant, to transfer heat from the core to steam used to power the electricity generating turbines. FBRs cooled by liquid metals other than sodium have been built, some early FBRs such as Clementine used mercury, Lead-cooled fast reactor have also been constructed, as well as other experimental reactors using Lead-bismuth eutectic or NaK, a sodium-potassium alloy. Mercury and NaK have the advantage that they are liquids at room temperature, which is convenient for experimental rigs but less important for pilot or full-scale power stations, where their chemical toxicity and cost respectively leave them as less attractive options. The Soviet Union used lead–bismuth coolant in some naval reactors. BREST-OD-300 is a later Russian design that uses lead coolant. Its first concrete was poured in June 2021. The SVBR-100 design specifies lead-bismuth eutectic as its coolant. Three of the proposed generation IV reactor types use a fast-neutron spectrum:
== Manufacturing == The vaccine candidate can be made in a lyophilized powder form, allowed it to be shipped and stored between 2 and 8 °C (36 and 46 °F). In August 2021, Arcturus Therapeutics entered a partnership with Vinbiocare, a unit of Vingroup to conduct clinical trials of ARCT-154 COVID-19 vaccine, developed created using Arcturus’ STARR mRNA technology, in Vietnam and establish a manufacturing facility a factory in Hòa Lạc Hi-tech Park, Hanoi, which requires an estimated investment of $200 million and has the capacity to make 200 million doses per year. It is expected that Vingroup will produce its first batches of the vaccine in early 2022. Arcturus will provide to Vinbiocare access to "proprietary technologies and processes for the manufacture" of its vaccines, as well as an exclusive license to manufacture them solely for sales and use in Vietnam. This includes all of Arcturus’ other Covid-19 vaccines such as ARCT-021 and other vaccines in the future for disease prevention in Vietnam. Vinbiocare will pay $40m upfront, be responsible for technology transfer costs, and "pay for mRNA drug substance supplied by Arcturus and royalties on vaccines produced at the facility".
== Ruler of Xikang (1933–1949) == After the disastrous Two-Liu War, Liu Wenhui retreated into Xikang, basing himself in the town of Ya'an. He focused his energies on ruling the region, which he aimed to establish as an official province of China. Kim Hee-shin believes that facing the need to secure his rule in Xikang, Liu began taking an interest in the province's affairs.
Sources: en.wikipedia.org
Hand therapy is often recommended. Approximately six weeks after surgery the patient is able completely to use the hand. The average recurrence rate is 39% after a fasciectomy after a median interval of about four years.
== Contraindications == Contraindications include the coadministration of terfenadine, astemizole, cisapride, pimozide, or carbamazepine. Nefazodone is contraindicated in patients who were withdrawn from nefazodone because of evident liver injury as well as those that have shown hypersensitivity to the drug, its inactive ingredients, or other phenylpiperazine antidepressants. Furthermore, the coadministration of triazolam and nefazodone should be avoided for all patients, including the elderly, since it causes a significant increase in the plasma level of triazolam and not all commercially available dosage forms of triazolam permit a sufficient dosage reduction. If coadministrated, a 75% reduction in the initial dosage of triazolam is recommended.
This use a treatment for disease was pioneered in 1890 by Emil von Behring and Shibasaburo Kitasato, who first demonstrated that the endotoxin from the infectious diseases diphtheria and tetanus could be used to prevent or cure non-immunized animals using serum transfusions from an immune animal to a susceptible one. Building on in this logic, and at the same session of the Society of Biology in Paris on February 10, 1894, Albert Calmette at the Pasteur Institute and independently Césaire Phisalix and Gabriel Bertrand at the Department of Pathology and Chemistry in the National Museum of National History in France, announced that they had achieved treatment of a vulnerable animal with serum from an immunized one both using snake venom. Calmette went on subsequently to immunize horses using venom from Indian cobras, and the resulting Serum Antivenimeux (antivenomous serum) became the first commercially available antivenom product. In 1895 Sir Thomas Fraser, Professor of Medicine at the University of Edinburgh, also produced a serum to act against cobra venom. His "antivenene" was effective in the laboratory. In 1901, Vital Brazil, working at the Instituto Butantan in São Paulo, Brazil, developed the first monovalent and polyvalent antivenoms for Central and South American Crotalus and Bothrops snakes, as well as for certain species of venomous spiders, scorpions, and frogs. In Mexico in 1905, Daniel Vergara Lope developed an antivenom against scorpion venom, by immunizing dogs. In Australia, the Commonwealth Serum Laboratories (CSL) began antivenom research in the 1920s.
Sources: en.wikipedia.org
ribonucleotide reductase (RNR) Also ribonucleoside diphosphate reductase. An enzyme which catalyzes the formation of deoxyribonucleotides via the reductive dehydroxylation of ribonucleotides, specifically by removing the 2' hydroxyl group from the ribose ring of ribonucleoside diphosphates (rNDPs). RNR plays a critical role in regulating the overall rate of DNA synthesis such that the ratio of DNA to cell mass is kept constant during cell division and DNA repair.
Carbon nanobuds are a newly created material combining two previously discovered allotropes of carbon: carbon nanotubes and fullerenes. In this new material, fullerene-like "buds" are covalently bonded to the outer sidewalls of the underlying carbon nanotube. This hybrid material has useful properties of both fullerenes and carbon nanotubes. In particular, they have been found to be exceptionally good field emitters. In composite materials, the attached fullerene molecules may function as molecular anchors preventing slipping of the nanotubes, thus improving the composite's mechanical properties. A carbon peapod is a novel hybrid carbon material which traps fullerene inside a carbon nanotube. It can possess interesting magnetic properties with heating and irradiation. It can also be applied as an oscillator during theoretical investigations and predictions. In theory, a nanotorus is a carbon nanotube bent into a torus (doughnut shape). Nanotori are predicted to have many unique properties, such as magnetic moments 1000 times larger than that previously expected for certain specific radii. Properties such as magnetic moment, thermal stability, etc. vary widely depending on the radius of the torus and the radius of the tube. Graphenated carbon nanotubes are a relatively new hybrid that combines graphitic foliates grown along the sidewalls of multiwalled or bamboo-style CNTs. The foliate density can vary as a function of deposition conditions (e.g., temperature and time) with their structure ranging from a few layers of graphene (< 10) to thicker, more graphite-like.
==== Knight Grand Cross of the Royal Victorian Order (GCVO) ==== The Most Reverend and Right Honourable Justin Portal Welby, Archbishop of Canterbury, on the occasion of the Coronation of Their Majesties The King and The Queen.
== External links == Clinical Laboratory Improvement Amendments (CLIA), Centers for Medicare & Medicaid Services (CMS) CLIA Regulations Assessment Workgroup, CDC Clinical Laboratory Improvement Advisory Committee (CLIAC) CLIA Laboratory Lookup, CMS S&C's Quality, Certification and Oversight Reports (QCOR)
Sources: en.wikipedia.org
GSH is the reduced thiol form, while GSSG is the disulfide-linked oxidized dimer. The GSH:GSSG ratio is used as a redox indicator, though the ratio can vary with sample handling and cell type.
Glutathione is present in many foods, including meats, poultry, fish, some vegetables, and fruits. Cooking, storage, and digestion affect the amounts available for absorption.
Yes, both enzymatic steps in glutathione synthesis consume ATP. The first step, catalyzed by glutamate-cysteine ligase, is usually rate-limiting.
Preanalytical factors such as sample type, time to processing, and stabilization method can change GSH and GSSG amounts. Analytical method and calibration also contribute to variation. Comparing absolute values across studies requires caution.